Seth Ettenberg
Directeur Général chez BlueRock Therapeutics Canada ULC
Profil
Seth Ettenberg is the President & Chief Executive Officer at BlueRock Therapeutics Canada ULC and the President, Chief Executive Officer & Director at BlueRock Therapeutics LP.
He previously served as the Chief Scientific Officer at Cogent Biosciences, Inc. Dr. Ettenberg holds a doctorate degree from the Uniformed Services University of the Health Sciences.
Postes actifs de Seth Ettenberg
| Sociétés | Poste | Début |
|---|---|---|
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Directeur Général | 01/08/2021 |
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Directeur Général | 01/08/2021 |
Anciens postes connus de Seth Ettenberg
| Sociétés | Poste | Fin |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 02/03/2020 |
Formation de Seth Ettenberg
| Uniformed Services University of the Health Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COGENT BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company is based in Cambridge, MA. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. BlueRock Therapeutics' lead clinical program, Bemdaneprocel (BRT-DA01), is in phase I clinical trials for Parkinson's disease. BlueRock Therapeutics was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG. Seth Ettenberg has been the CEO of the company since 2020. | Commercial Services |
